These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36519019)

  • 1. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
    Ibusuki R; Yoneshima Y; Hashisako M; Matsuo N; Harada T; Tsuchiya-Kawano Y; Kishimoto J; Ota K; Shiraishi Y; Iwama E; Tanaka K; Oda Y; Okamoto I
    Transl Lung Cancer Res; 2022 Nov; 11(11):2208-2215. PubMed ID: 36519019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study.
    Mori S; Maiguma T; Yoshii K; Moriya Y; Takada R; Shinkai F; Haruki Y; Hashimoto H; Komoto A; Takayanagi K; Tamura K; Okura Y; Sugiyama T; Shimada K
    Am J Cancer Res; 2024; 14(8):3852-3858. PubMed ID: 39267683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.
    Iso H; Hisakane K; Mikami E; Suzuki T; Matsuki S; Atsumi K; Nagata K; Seike M; Hirose T
    Transl Lung Cancer Res; 2023 Sep; 12(9):1850-1861. PubMed ID: 37854151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
    Nishioka N; Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Masui T; Sai N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Front Immunol; 2024; 15():1399889. PubMed ID: 39076994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer.
    Nakao A; Inoue H; Ikeuchi N; Igata F; Aoyama T; Hamasaki M; Arima H; Fujita M
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
    Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
    Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
    J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
    Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
    BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
    Zhai X; Jing X; Li J; Tian Y; Xu S; Wang M; Zhu H
    Front Oncol; 2020; 10():556275. PubMed ID: 33102221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
    Tanimura K; Takeda T; Kataoka N; Yoshimura A; Nakanishi K; Yamanaka Y; Yoshioka H; Honda R; Uryu K; Fukui M; Chihara Y; Takei S; Kawachi H; Yamada T; Tamiya N; Okura N; Yamada T; Murai J; Shiotsu S; Kurata T; Takayama K
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
    Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M
    J Thorac Dis; 2019 May; 11(5):1919-1928. PubMed ID: 31285885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
    Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
    Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between TTF-1 Expression and PFS of Pemetrexed-containing Chemotherapy in Non-squamous-NSCLC Patients With and Without Driver Genes.
    Okauchi S; Miyazaki K; Shiozawa T; Satoh H; Hizawa N
    Cancer Diagn Progn; 2023; 3(1):53-60. PubMed ID: 36632586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    Yang Y; Sun J; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Ma R; Bi M; Ren X; Zhou J; Li B; Song Y; Feng J; Li J; He Z; Zhou R; Li W; Lu Y; Zhou H; Wang S; Sun L; Puig O; Mancao C; Peng B; Fang W; Xu W; Zhang L
    J Thorac Oncol; 2021 Dec; 16(12):2109-2120. PubMed ID: 34358724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.